<DOC>
	<DOCNO>NCT02567461</DOCNO>
	<brief_summary>It uncommon patient require dual antiplatelet therapy ( DAPT ) also need treated oral anticoagulant therapy , atrial fibrillation ( AF ) . Warfarin clopidogrel still widely utilized oral anticoagulant P2Y12 receptor inhibitor , respectively . However , past year , several non-vitamin K antagonist oral anticoagulant , include edoxaban , study set AF show encouraging safety efficacy profile compare warfarin . However , effect edoxaban combination DAPT set patient coronary artery disease ( CAD ) unexplored . Moreover , role edoxaban part dual antithrombotic treatment strategy , include clopidogrel stop aspirin , represent another important area clinical interest . This investigation prospective , randomize , parallel-design , open label , pharmacodynamic study conduct patient CAD DAPT aspirin clopidogrel test two different edoxaban dose regimen addition DAPT aspirin clopidogrel , well combination clopidogrel ( stop aspirin ) .</brief_summary>
	<brief_title>Edoxaban Patients With Coronary Artery Disease Dual Antiplatelet Therapy With Aspirin Clopidogrel</brief_title>
	<detailed_description>Dual antiplatelet therapy ( DAPT ) aspirin P2Y12 receptor antagonist pivotal treatment patient coronary artery disease ( CAD ) undergo percutaneous coronary intervention ( PCI ) patent follow acute coronary syndrome ( ACS ) . Importantly , uncommon patient require DAPT also need treated oral anticoagulant therapy , atrial fibrillation ( AF ) . Warfarin clopidogrel still widely utilized oral anticoagulant P2Y12 receptor inhibitor , respectively . However , treatment regimen show associate increase risk bleeding , well ischemic complication . Over past year , several non-vitamin K antagonist oral anticoagulant ( NOACs ) , include edoxaban , study set AF show encouraging safety efficacy profile compare warfarin . In phase III ENGAGE AF-TIMI 48 trial , edoxaban ( 60mg 30mg once/daily ) non-inferior warfarin respect prevention stroke systemic embolism associate significantly low rate bleed death cardiovascular cause , patient AF . However , effect edoxaban combination DAPT set patient CAD unexplored . This may indeed represent limitation uptake edoxaban modern day clinical practice ~10 % patient AF also CAD require PCI thus may require triple antithrombotic therapy . Moreover , role edoxaban part dual antithrombotic treatment strategy , include clopidogrel stop aspirin , represent another important area clinical interest potential reduce risk bleed preserve protection ischemic event . This investigation prospective , randomize , parallel-design , open label , pharmacodynamic study conduct patient CAD DAPT aspirin clopidogrel test two different edoxaban dose regimen ( 60mg 30mg once/daily ) addition DAPT aspirin clopidogrel , well combination clopidogrel ( stop aspirin ) .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Inclusion criterion : 1 . Patients angiographically document CAD ( previous PCI ACS ) . 2 . On DAPT lowdose aspirin ( 81mg od ) clopidogrel least 30 day per standardofcare . 3 . Age 18 . Exclusion criterion : 1 . Active pathological bleeding , history clinically significant bleed event , deem increase risk bleeding . 2 . CrCL &lt; 15mL/min 3 . Any clinical indication anticoagulant therapy 4 . Acute coronary event past 90 day 5 . Prior hemorrhagic stroke intracranial hemorrhage 6 . Ischemic stroke/transient ischemic attack past 6 month 7 . Chronic use nonsteroidal antiinflammatory drug 8 . On treatment rifampin ( induce Pgp transporter ) 9 . Known moderate severe hepatic impairment ( ChildPugh B C ) . 10 . On treatment antiplatelet agent aspirin clopidogrel past 30 day . 11 . Platelet count &lt; 80x106/mL 12 . Hemoglobin &lt; 10g/dL 13 . Hemodynamic instability 14 . Pregnant female [ woman childbearing age must use reliable birth control ( i.e . oral contraceptive ) participate study ] .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>dual antiplatelet therapy</keyword>
	<keyword>clopidogrel</keyword>
	<keyword>aspirin</keyword>
	<keyword>edoxaban</keyword>
</DOC>